UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

A new study by UCSF researchers reveals that long-acting injectable treatments offer a promising alternative for HIV patients who find it challenging to adhere to daily pill regimens. This ...

Patients who struggle to take daily HIV pills can benefit from long-acting ... the UCSF HIV/AIDS clinic at Zuckerberg San Francisco General Hospital. They studied data from 370 patients ...